Citigroup Maintains Buy on Guardant Health, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $40 to $50.
August 04, 2023 | 3:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Buy rating on Guardant Health and raises the price target from $40 to $50, which could lead to a positive impact on the stock.
The raised price target by Citigroup indicates a positive outlook for Guardant Health. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100